Bioxytran, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 2.46 million compared to USD 4.03 million a year ago. Basic loss per share from continuing operations was USD 0.02 compared to USD 0.04 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1106 USD | +0.55% | +9.40% | -26.27% |
Apr. 19 | Bioxytran, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 19 | Bioxytran, Inc. Announces Board Changes | CI |
1st Jan change | Capi. | |
---|---|---|
-26.27% | 19.35M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- BIXT Stock
- News Bioxytran, Inc.
- Bioxytran, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022